Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This is interventional study and single arm study. N/A
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.
ER positive.
The patient must be postmenopausal woman.
The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will necessarily precede and will be independent of the decision to enroll patients in the study).
You may not be if
Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving Aromasin® treatment, there is evidence of a local relapse or distant metastasis of breast cancer, or a second primary cancer.
Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin®).
Clareo Health | Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
